Scott Treiber brings a wealth of expertise to Elligo spanning more than 25 years. Over the last decade, Treiber has been instrumental in the growth of several organizations. At inVentiv (now Syneos), Treiber assembled a global partnership with five regional CROs and assimilated a U.S. CRO. A few years later, after Theorem was purchased by Chiltern (now Covance), Treiber expanded a therapeutically diverse biopharmaceutical development division helping to create the top midsized CRO in the industry. He also held senior positions at Hospira and PharmaNet.
In his executive management positions, Treiber led and grew diverse functional groups including clinical operations/development, medical affairs, data management, statistics, medical writing and pharmacovigilance. His therapeutic expertise lies in neuroscience, oncology, pain, respiratory and gastroenterology.
Treiber earned a Ph.D. in neuroscience from the University of California Santa Cruz, an MBA from Ellis College (New York Institute of Technology) and a BA from the University of Iowa.